Valuation: GENFIT

Market Cap 417M 467M 389M 353M 665M 45.2B 671M 4.67B 1.83B 22.97B 1.75B 1.71B 73.87B P/E 2026 *
9.7x
P/E 2027 * 89.1x
Enterprise Value 277M 310M 258M 235M 442M 30.03B 446M 3.1B 1.21B 15.26B 1.16B 1.14B 49.08B EV / Sales 2026 *
2.55x
EV / Sales 2027 * 2.69x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
3 months+46.51%
6 months+51.01%
Current year+162.50%
Current year 7.26
Extreme 7.26
16.5
1 year 4.14
Extreme 4.14
16.5
3 years 2.95
Extreme 2.95
16.5
5 years 2.95
Extreme 2.95
16.5
10 years 0
Extreme 0
36.86
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-.--% - - 511M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.63%+293.39%+638.59% 43.05B
+0.30%-0.71%+29.05%+29.74% 42.48B
-3.82%-2.41%-0.27%+102.63% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-4.95%-13.38%-15.78% 23.93B
-1.24%-7.47%-37.90%+309.96% 22.22B
Average -4.11%-2.63%+36.80%+142.85% 42.9B
Weighted average by Cap. -4.84%-1.88%+43.24%+135.10%

Financials

2026 *2027 *
Net sales 109M 122M 101M 91.96M 173M 11.77B 175M 1.22B 475M 5.98B 456M 446M 19.23B 130M 145M 121M 110M 207M 14.09B 209M 1.45B 569M 7.16B 546M 534M 23.02B
Net income 42.71M 47.83M 39.85M 36.2M 68.11M 4.63B 68.77M 478M 187M 2.35B 180M 176M 7.57B 10.37M 11.61M 9.67M 8.78M 16.53M 1.12B 16.69M 116M 45.41M 571M 43.59M 42.64M 1.84B
Net Debt -140M -157M -130M -119M -223M -15.17B -225M -1.57B -613M -7.71B -588M -575M -24.79B -67.56M -75.65M -63.02M -57.25M -108M -7.33B -109M -757M -296M -3.72B -284M -278M -11.97B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.120EUR
Average target price
17.48EUR
Spread / Average Target
+91.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT